TITLE

Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs

AUTHOR(S)
Denis, Alain; Mergaert, Lut; Fostier, Christel; Cleemput, Irina; Hulstaert, Frank; Simoens, Steven
PUB. DATE
October 2011
SOURCE
PharmacoEconomics;2011, Vol. 29 Issue 10, p883
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Orphan medicinal products are designed to diagnose or treat rare diseases that are serious, life threatening or chronically debilitating and that affect 50 or fewer people in every 100 000 in the EU. In Belgium, the Drug Reimbursement Committee (DRC) evaluates reimbursement requests for orphan drugs based on multiple criteria: the therapeutic value, price and proposed reimbursement tariff; the importance of the drug in clinical practice; and the budget impact of the drug. Objectives: This study aimed to assess reimbursement dossiers of orphan drugs in Belgium and to compare them with the clinical evidence submitted to the European Medicines Agency (EMA). Methods: A qualitative analysis examined all reimbursement dossiers of orphan drugs that were submitted in Belgium between January 2002 and June 2008. The following information was extracted from each dossier: description of the orphan drug; indication; reimbursement status; therapeutic value and needs; budget impact; and number of registered indications. For selected orphan drugs, an in-depth analysis extracted and compared information about the clinical trials, their primary endpoints and results from EMA documents (i.e. the marketing authorization application file, European public assessment report and summary of product characteristics) and the Belgian reimbursement dossiers. Results: Reimbursement was awarded to the majority of orphan drugs. In addition to the official criteria, other negotiable factors, such as price adjustments, employment incentives, patient population restrictions and funding of diagnostic tests by the company, seemed to play a role in the reimbursement decision. Despite the low number of patients, randomized controlled trials were conducted for many orphan drugs. Budget-impact analyses were simplistic and did not consider the impact across multiple indications. Some differences were also observed between the clinical evidence submitted to the EMA and that submitted to the Belgian DRC. Conclusions: In addition to the official criteria, other negotiable factors, such as price adjustments and employment incentives, may play a role in Belgian reimbursement decisions of orphan drugs. Some differences have also been noted between the clinical evidence reported in EMA documents and the evidence included in Belgian reimbursement dossiers of orphan drugs. There appears to be a need for further standardization of Belgian reimbursement applications and for European cooperation in sharing clinical evidence of orphan drugs.
ACCESSION #
71654882

 

Related Articles

  • Combo lowered cholesterol, improved triglycerides.  // Cardiology Today;Feb2008, Vol. 11 Issue 2, p20 

    The article reports on the result of the phase-3 clinical trial titled SEACOAST in the U.S. The 24-week clinical trial compared simvastatin alone with a combination of drugs niacin and simvastatin in 600 patients with non-HDL. Moreover, result shows that 6% of the patients on the combination of...

  • News in brief . . .  // Reactions Weekly;6/18/2005, Issue 1056, p2 

    Presents updates on issues and events concerning medical researches in the U.S. as of June 2005. Reason for the temporary suspension of the clinical trial for the AV 1101 drug; Recommendations of Bristol-Myers Squibb for pregnant women taking the Sustiva drug; Postponement of the patient...

  • Coding for Clinical Trials. Parman, Cindy C. // Journal of Oncology Management;Nov/Dec2004, Vol. 13 Issue 6, p7 

    Although CMS reimburses for routine care associated with clinical trials. it is essential that the correct diagnosis code, modifier, and, where necessary. HCPCS Level 11 procedure code he assigned to accurately report these qualifying trial services. Remember that not all insurance payors will...

  • Barriers to Clinical Trial Enrollment: Are State Mandates the Solution? Hillner, Bruce E. // JNCI: Journal of the National Cancer Institute;7/21/2004, Vol. 96 Issue 14, p1048 

    Comments on issues related factors that prevent cancer patients from participating in clinical trials in the U.S. Significance of deriving optimal medical care from patients participating in comparative randomized clinical trials; Variety of suggestions to enhance public participation in...

  • Cancer Trial Enrollment After State-Mandated Reimbursement. Gross, C. P.; Murthy, V.; Li, Y.; Kaluzny, A. D.; Krumholz, H. M. // JNCI: Journal of the National Cancer Institute;7/21/2004, Vol. 96 Issue 14, p1063 

    Recruitment of patients into cancer research studies is exceedingly difficult, particularly for early phase trials. Payer reimbursement policies are a frequently cited barrier. We examined whether state policies that ensure coverage of routine medical care costs for cancer trial participants are...

  • What Shall We Do About the Children? O'Donnell, Peter // Applied Clinical Trials;Jun2004, Vol. 13 Issue 6, p30 

    The European Union (EU) is trying to get its pediatric medicines proposal right. So the EU has been talking to everyone who will listen in a bid to get it right. Still wounded from the hostility to its clinical trials rules that came into effect in May, it is anxious to head off more criticism...

  • TREM-1: A new regulator of innate immunity in sepsis syndrome. Nathan, Carl; Ding, Aihao // Nature Medicine;May2001, Vol. 7 Issue 5, p530 

    Although we have drugs and biologics designed to interfere with the innate immune response, none has been shown to shut down the massive inflammatory reaction that occurs during sepsis. A new pro-inflammatory myeloid-cell receptor might make a better target.

  • Patient study explores trial results question.  // European Pharmaceutical Executive;May/Jun2006, p14 

    The article reports that Taxotere as Adjuvant ChemoTherapy (TACT) has explored the question of if and how patients should be told of the results of clinical trials in which they participate. TACT's study revealed that posting results directly to patients' homes was preferred and that most of the...

  • Trials shock fuels public interest.  // European Pharmaceutical Executive;May/Jun2006, p16 

    The article reports on how the Parexel clinical trial elicited a surge of interested volunteers from the general public. Enter Trials is a web site through which patients can register to participate in clinical trials. It reported that after the Parexel incident, its server hits rose from...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics